Biomarkers.

Background: Early-onset Alzheimer's disease (EOAD), manifesting before age 65, demands nuanced diagnostic approaches. FDG18-PET unveils metabolic insights, the MRI scale captures structural changes, and ACE-R assesses cognitive impairment details. A holistic evaluation enhances diagnostic precision and enriches our understanding of cognitive decline in early-onset presentations.

Biomarkers.

Background: Early-onset Alzheimer's disease (EOAD), distinct from late-onset cases, tends to present with atypical cognitive decline, such as, progressive aphasia, apraxia, visuospatial and comportmental impairments,. This study aims to investigate correlations between clinical presentation and PET imaging findings in EOAD patients.

Method: A retrospective analysis was conducted on CSF confirmed EOAD patients.

Alzheimer's Imaging Consortium.

Background: Early-onset Alzheimer's disease (EOAD), distinct from late-onset cases, tends to present with atypical cognitive decline, such as, progressive aphasia, apraxia, visuospatial and comportmental impairments,. This study aims to investigate correlations between clinical presentation and PET imaging findings in EOAD patients.

Method: A retrospective analysis was conducted on CSF confirmed EOAD patients.

Alzheimer's Imaging Consortium.

Background: Early-onset Alzheimer's disease (EOAD), manifesting before age 65, demands nuanced diagnostic approaches. FDG18-PET unveils metabolic insights, the MRI scale captures structural changes, and ACE-R assesses cognitive impairment details. A holistic evaluation enhances diagnostic precision and enriches our understanding of cognitive decline in early-onset presentations.